MG
KURA icon

Michael Gelband’s Kura Oncology KURA Stock Holding History

Michael Gelband’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-229,728
Closed -$1.87M – 1834
2026
Q1 		$1.87M Buy
229,728
+205,175
+836% +$1.76M 0.01% 808
2025
Q4 		$255K Buy
24,553
+6,714
+38% +$70.4K ﹤0.01% 1347
2025
Q3 		$158K Buy
+17,839
New +$127K ﹤0.01% 1408
2025
Q2 		– Sell
-240,746
Closed -$1.59M – 1737
2025
Q1 		$1.59M Sell
240,746
-56,488
-19% -$440K 0.02% 778
2024
Q4 		$2.59M Buy
297,234
+242,263
+441% +$3.49M 0.02% 627
2024
Q3 		$1.07M Buy
+54,971
New +$1.11M 0.01% 954
2024
Q1 		– Sell
-39,349
Closed -$566K – 1743
2023
Q4 		$566K Sell
39,349
-1,960
-5% -$19.3K ﹤0.01% 1004
2023
Q3 		$377K Buy
41,309
+10,685
+35% +$108K ﹤0.01% 1334
2023
Q2 		$324K Sell
30,624
-86,810
-74% -$1.03M ﹤0.01% 1510
2023
Q1 		$1.44M Buy
117,434
+34,394
+41% +$429K 0.01% 1013
2022
Q4 		$1.03M Sell
83,040
-42,709
-34% -$621K 0.02% 927
2022
Q3 		$1.72M Buy
125,749
+73,419
+140% +$1.13M 0.02% 869
2022
Q2 		$959K Buy
52,330
+33,540
+178% +$482K 0.01% 1100
2022
Q1 		$302K Buy
+18,790
New +$271K ﹤0.01% 1754
2021
Q4 		– Sell
-19,581
Closed -$367K – 2399
2021
Q3 		$367K Buy
19,581
+9,109
+87% +$172K 0.01% 1536
2021
Q2 		$218K Buy
+10,472
New +$260K ﹤0.01% 1931
2021
Q1 		– Sell
-16,868
Closed -$551K – 2368
2020
Q4 		$551K Sell
16,868
-10,975
-39% -$386K 0.01% 1184
2020
Q3 		$853K Buy
27,843
+8,674
+45% +$192K 0.02% 753
2020
Q2 		$312K Buy
+19,169
New +$277K 0.01% 1299
2020
Q1 		– Sell
-10,773
Closed -$148K – 1381
2019
Q4 		$148K Buy
+10,773
New +$160K ﹤0.01% 1388

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Michael Gelband's KURA Position: Q2 2026 in Review

Michael Gelband sold out of Kura Oncology (KURA) in Q2 2026, closing a stake of 229,728 shares — an estimated $1.87M sold.

Michael Gelband first reported a position in KURA in Q4 2019 and held it in 20 quarters. The position peaked at $2.59M in Q4 2024. 219 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Michael Gelband reported no remaining Kura Oncology position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 229,728 Kura Oncology shares in Q2 2026, an estimated $1.87M.
  • Michael Gelband first reported a position in Kura Oncology in Q4 2019 and held it in 20 quarters.
  • Michael Gelband's Kura Oncology position peaked at $2.59M in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.